Company Description
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company.
The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.
Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease.
Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
| Country | United States |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 56 |
| CEO | David Hochman |
Contact Details
Address: 150 Union Square Drive New Hope, Pennsylvania 18938 United States | |
| Phone | 212 862 5797 |
| Website | orchestrabiomed.com |
Stock Details
| Ticker Symbol | OBIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001814114 |
| CUSIP Number | 68572M106 |
| ISIN Number | US68572M1062 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| David Hochman | Chief Executive Officer |
| Andrew Taylor | Chief Financial Officer |
| Darren Sherman | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 23, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 10, 2024 | 144 | Filing |
| Sep 10, 2024 | 144 | Filing |
| Sep 9, 2024 | 144 | Filing |
| Sep 9, 2024 | 144 | Filing |
| Sep 6, 2024 | 144 | Filing |
| Sep 6, 2024 | 144 | Filing |
| Sep 5, 2024 | 144 | Filing |